Radioterapia moderadamente hipofracionada no câncer de mama inicial ou in situ é recomendada como novo padrão de terapia

Referência

1. Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Krause M, Stenbygaard L, Mjaaland I, Schreiber A, Kasti UM, Overgaard J. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial. Journal of Clinical Oncology. 2020 Sep: JCO-20.